Introduction to Pharmacoepidemiology

Saturday, 8 September 2012
09:00 to 16:00
Population Health Congress, Room C4-17, City East Campus, University of South Australia
Frome Rd

With the growing availability of large healthcare databases, non-experimental studies of prescription medications are becoming increasingly common. 

However, appropriate design and analysis of such studies can be challenging.  In this workshop we provide an intensive introduction to the field of pharmacoepidemiology. 

We review the data used in pharmacoepidemiology and the central threats to validity of studies medications, including the healthy user bias, immortal person time bias, and various types of confounding bias. We then discuss approaches to mitigate these biases through design and analysis. 

The workshop will cover the comparative new user design, self-controlled designs, propensity score methods, and instrumental variable approaches.  We will also discuss some additional topics in the field, including studies of medication adherence, disparities, and active safety surveillance of medical products.


Assoc. Prof. Alan Brookhart

Department of Epidemiology
UNC Gillings School of Global Public Health, UNC-Chapel Hill

Dr. M. Alan Brookhart is an Associate Prof of Epidemiology and Medicine at the University of North Carolina at Chapel Hill. His research is focused primarily on the development and application of new statistical methods and study designs for epidemiologic studies of medications using large clinical and healthcare utilization databases. In this area, he has made contributions to the development of quasi-experimental and instrumental variable approaches that can be used to estimate causal effects in the presence of unmeasured or poorly recorded confounding variables.

He has also been involved with the development of propensity score and marginal structural model methodology and has also developed new epidemiologic approaches for studying medication adherence and use of healthcare services. Substantively, he is interested in the effects medications in the elderly and patients with end-stage renal disease.

Microsoft Office document icon Brookhart Workshop111 KB
PDF icon Brookhart Booklet4.8 MB